The new facility will produce biologic drugs and Keytruda, becoming Merck’s first in-house US site to make the blockbuster cancer treatment, the company said.

Merck is particularly exposed to the tariff threat, as much of its production of Keytruda takes place at facilities in ...

The Delaware facility will ensure a domestic supply of biologic drugs including the cancer drug Keytruda.

Merck Wilmington Biotech will serve as a launch and commercial production facility and the future U.S. home for KEYTRUDA.

Merck (MRK) is reportedly looking to expand its U.S. manufacturing presence with a $1 billion facility in Delaware, becoming ...

U.S. drugmaker Merck said on Tuesday it is investing $1 billion in a new Delaware plant to expand domestic production as it ...

The firm reported revenues of $15.53 billion and adjusted earnings per share of $2.22, surpassing consensus predictions of ...

Merck, the New Jersey-based drug giant, is spending $1 billion on a new Delaware factory to bring production of its ...

It will build a Wilmington, Delaware facility dedicated to making its cancer drug, Keytruda, for U.S. patients.

Merck starts construction on a $1B biologics facility in Wilmington, Del., expected to create 500+ jobs and support Keytruda production.

Merck (NYSE:MRK) is reportedly looking to expand its U.S. manufacturing presence with a $1 billion facility in Delaware, ...